{"id":2200,"date":"2025-04-13T13:58:38","date_gmt":"2025-04-13T13:58:38","guid":{"rendered":"https:\/\/www.cravacin.com\/?p=2200"},"modified":"2025-04-15T12:47:10","modified_gmt":"2025-04-15T12:47:10","slug":"how-deucravacitinib-bring-solution-for-plaque-psoriatic-patients","status":"publish","type":"post","link":"https:\/\/www.ruxotor.com\/Tablet\/how-deucravacitinib-bring-solution-for-plaque-psoriatic-patients\/","title":{"rendered":"How Deucravacitinib bring solution for Plaque Psoriatic patients?"},"content":{"rendered":"

Psoriasis affects over 8 million individuals in the United States. The most prevalent form is plaque psoriasis, which impacts 80 to 90 percent of those diagnosed with the condition. This type of psoriasis is marked by inflamed, scaly patches of skin known as “plaques,” which can be itchy and sometimes painful.
\nOn lighter skin tones, these plaques often appear red with a silvery layer of dead skin. On darker skin tones, they may present as purplish, gray, or dark brown patches.
\n\u201cPlaque psoriasis is a long-term condition that can impact not only the skin but also the joints and nails,\u201d explained Dr. Atieh Jibbe, associate director of surgery in the Division of Dermatology at The University of Kansas Health System, in an interview with Healthline. \u201cIts development is influenced by a combination of genetic, autoimmune, and environmental factors.\u201d
\nDr. Atieh Jibbe noted that the new drug, SOTYKTU(Deucravacitinib), may be a major advancement for people with plaque psoriasis who haven\u2019t responded well to existing treatments. \u201cPsoriasis involves various immune pathways that biologic drugs typically target,\u201d she explained. SOTYKTU(Deucravacitinib) could be a game-changer for patients who haven\u2019t had success with other biologics, due to its novel mechanism of action.\u201d
\nClinical trials revealed the drug led to significant improvements in symptoms, skin clearance, and overall quality of life.
\nDr. Tien Nguyen, a dermatologist at MemorialCare Orange Coast Medical Center in California and a clinical trial investigator, highlighted that SOTYKTU(Deucravacitinib) could be particularly beneficial for patients who cannot use or are uncomfortable with injectable treatments. \u201cThis medication can make a big difference,\u201d he said. \u201cSome people with moderate to severe psoriasis aren\u2019t good candidates for injections, or they have a fear of needles. Since injectables must be refrigerated, they\u2019re also inconvenient for frequent travelers or students living in dorms. An oral pill gives us another much-needed option.\u201d
\nWhile Dr. John K. Fiorentino acknowledged the drug may not be quite as effective as the newest biologics, he believes it could serve as a more affordable option. \u201cBecause it\u2019s a small molecule and less costly to manufacture, I hope it\u2019s priced lower than biologics, which could reduce healthcare costs,\u201d he said. \u201cI would absolutely consider prescribing it\u2014potentially even as a first-line treatment\u2014for patients without premium insurance or those hesitant about self-injections.
\nThe generic version of SOTYKTU is made available by Everest Pharmaceuticals Limited Bangladesh under brand name CRAVACIN where treatment access is not like first world countries.
\nReference:\u00a0 \u00a0 \u00a0https:\/\/www.healthline.com\/health-news\/fda-approves-new-drug-sotyktu-for-treatment-of-plaque-psoriasis<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Psoriasis affects over 8 million individuals in the United States. The most prevalent form is plaque psoriasis, which impacts 80 to 90 percent of those diagnosed with the condition. This type of psoriasis is marked by inflamed, scaly patches of skin known as “plaques,” which can be itchy and sometimes painful. On lighter skin tones, […]<\/p>\n","protected":false},"author":1,"featured_media":2216,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[26],"tags":[],"class_list":["post-2200","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"_links":{"self":[{"href":"https:\/\/www.ruxotor.com\/Tablet\/wp-json\/wp\/v2\/posts\/2200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ruxotor.com\/Tablet\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ruxotor.com\/Tablet\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ruxotor.com\/Tablet\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ruxotor.com\/Tablet\/wp-json\/wp\/v2\/comments?post=2200"}],"version-history":[{"count":3,"href":"https:\/\/www.ruxotor.com\/Tablet\/wp-json\/wp\/v2\/posts\/2200\/revisions"}],"predecessor-version":[{"id":2210,"href":"https:\/\/www.ruxotor.com\/Tablet\/wp-json\/wp\/v2\/posts\/2200\/revisions\/2210"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ruxotor.com\/Tablet\/wp-json\/wp\/v2\/media\/2216"}],"wp:attachment":[{"href":"https:\/\/www.ruxotor.com\/Tablet\/wp-json\/wp\/v2\/media?parent=2200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ruxotor.com\/Tablet\/wp-json\/wp\/v2\/categories?post=2200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ruxotor.com\/Tablet\/wp-json\/wp\/v2\/tags?post=2200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}